ArticleThe New England journal of medicine2017
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.
David P Carbone et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1,489 papers cite itlatest 60 shown
this paperpooled ittrialcites it